Sandy Kimber is a senior scientist and manager within the infectious diseases team at Charles River Laboratories, Portishead. At Charles River she designs and implements pre-clinical research studies for a wide range of clients across the biologics and pharmaceutical sector. Sandy has worked on a variety of infectious disease vaccine candidates, immunomodulatory treatments, anti-microbials and anti-virals over the last 10 years. Her current position builds on her previous research as a post-doctoral researcher at Bristol University in partnership with ImmBio investigating a novel vaccine for the main causal agent of meningitis (Neisseria meningitidis). Her PhD at Sussex University used the genetics of Drosophila melanogaster to investigate nitric oxide signaling in relation to proliferation. Prior to this Sandy prepared vaccine candidates for Group A Streptococcus and Neisseria meningitidis for Microscience Ltd, later acquired by Emergent BioSolutions. As part of her undergraduate degree Sandy screened compounds for their chemotactic ability at Novartis in Vienna.